The Role of Pre-IPO Financial Indicators and Intermediaries in Aftermarket Performance and Survival in the US Biopharmaceutical Market-Reference-Cited by-同舟云学术

The Role of Pre-IPO Financial Indicators and Intermediaries in Aftermarket Performance and Survival in the US Biopharmaceutical Market

Published:2012-08-03 Issue:3-4 Volume:7 Page:127-139
ISSN:1872-5120
Container-title:Journal of Pharmaceutical Innovation
language:en
Short-container-title:J Pharm Innov

Author:

Williams David R.,Young Carlton C.

Publisher

Springer Science and Business Media LLC

Subject

Drug Discovery,Pharmaceutical Science

Link

http://link.springer.com/content/pdf/10.1007/s12247-012-9131-0.pdf

Reference64 articles.

1. Basu P, Joglekar G, Rai S, Suresh P, Vernon J. Analysis of manufacturing costs in pharmaceutical companies. J Pharm Innov. 2008;3:175–87.

2. Pharmaceutical Research and Manufacturers of America: Pharmaceutical industry profile 2007. http://www.phrma.org/files/Profile%202007.pdf (2007). Accessed 15 March 2008.

3. DiMasi JA, Grabowski HG. The cost of biopharmaceutical R&D: is biotech different? Manag Decis Econ. 2007;28:469–79.

4. Carleysmith SW, Dufton AM, Altria KD. Implementing lean sigma in pharmaceutical research and development: a review by practitioners. R&D Manag. 2009;39(1):95–106.

5. Danzon PM, Nicholson S, Pereira NS. Productivity in pharmaceutical-biotechnology R&D: the role of experience in alliances. J Health Econ. 2005;24(2):317–39.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Study of the Long-Term Performance After the Initial Public Offering of Korean Biopharmaceutical Companies;2024 Portland International Conference on Management of Engineering and Technology (PICMET);2024-08-04

2. Board characteristics and the amount of capital raised in the Malaysian IPO market;Journal of Multinational Financial Management;2017-12

3. Aftermarket Performance of Health Care and Biopharmaceutical IPOs: Evidence From ASEAN Countries;INQUIRY: The Journal of Health Care Organization, Provision, and Financing;2017-01-01

4. The initial public offering;The Funding of Biopharmaceutical Research and Development;2013